Inflammatory profile discriminates clinical subtypes in <i>LRRK2</i>‐associated Parkinson's disease

Abstract

Inflammation seems to be associated with the presence of a specific clinical subtype in PD_LRRK₂ that is characterized by a broad and more severely affected spectrum of motor and non-motor symptoms. The pro-inflammatory metabolites IL-8, MCP-1 and MIP-1-β as well as BDNF are interesting candidates to be included in biomarker panels that aim to differentiate subtypes in PD_LRRK₂ and predict progression.